TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33338583
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily, orally for 8 weeks
Study: 36187084
Drug: EXER (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXER (loading programme specific to Achilles tendon combined with physical therapy)
Study: 36187084
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference and satisfaction with treatment
Study: 34171280
Drug: Pharmacokinetic-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic-guided treatment group
Study: 34981324
Drug: Long biliopancreatic
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long biliopancreatic Roux-en-Y gastric bypass (L-RYGB)
Study: 32592273
Drug: Intra-dermal tranexamic
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-dermal tranexamic acid (TXA) injections
Study: 33220216
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with dihydroartemisinin-piperaquine
Study: 33220216
Drug: Single screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single screening and treatment with dihydroartemisinin-piperaquine
Study: 36049700
Drug: High-dose MVC-COV1901
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MVC-COV1901 (25 mcg)
Study: 36049700
Drug: Mid-dose MVC-COV1901
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose MVC-COV1901 (15 mcg)
Study: 34331403
Drug: Nuts (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuts (50 g day-1)
Study: 36195982
Drug: Top performing
Normalized name: Perform Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top performing text message (described vaccine as 'reserved for you')
Study: 33460240
Drug: iACT (Internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: iACT (Internet-delivered acceptance and commitment therapy)
Study: 32700215
Drug: Community-based diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based diabetes self-management education (DSME) plus 6 months of mHealth-enhanced peer support (12 weekly phone calls, then 3 monthly calls)
Study: 34835098
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group from a historic randomized controlled trial of ganciclovir for early treatment of CMV infection.
Study: 33147073
Drug: Wearable respiratory
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable respiratory monitor with daily in-application breathing exercise for 30 days
Study: 32139409
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (6000 mg/day)
Study: 35484697
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg + TCS
Study: 32186160
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (30-minute sessions, 3 times weekly for 6 weeks)
Study: 32186160
Drug: Routine conventional
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine conventional Western Medicine treatment alone
Study: 35106617
Drug: TDM-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDM-guided therapy (continuous infusion of piperacillin/tazobactam with dosing guided by daily TDM)
Study: 35106617
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose therapy (continuous infusion of piperacillin/tazobactam at 13.5 g/24 h if eGFR ≥ 20 mL/min)
Study: 35106617
Drug: TDM-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDM-guided therapy
Study: 35106617
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose therapy
Study: 33909732
Drug: Implant survival
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant survival probability for patients ≤ 70 years of age
Study: 33248581
Drug: ZnSO4 treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnSO4 treatment: 80 mg zinc/kg from ZnSO4
Study: 33248581
Drug: ISO treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISO treatment: 40 mg zinc/kg from ZnSO4 plus 40 mg zinc/kg from a zinc-amino acid complex
Study: 33248581
Drug: Organic treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic treatment: 40 mg zinc/kg from a zinc-amino acid complex
Study: 32759193
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 400 IU and 500 mg of calcium carbonate twice a day for 1 year
Study: 33277370
Drug: GVAX with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVAX with low-dose oral cyclophosphamide
Study: 33525212
Drug: SOF/LDP 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF/LDP 400/100 mg daily plus standard of care (n=42)
Study: 33348685
Drug: 280 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 g/day of frozen raspberries for 8 weeks
Study: 37671748
Drug: Pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics
Study: 34837121
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment 14 days prior to surgery
Study: 35152536
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of vitamin D3 (1ml every 4 weeks for a maximum of 3 sessions)
Study: 36118833
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) combined with Eye Movement Desensitization and Reprocessing (EMDR)
Study: 32409691
Drug: isatuximab 3
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: isatuximab 3 mg/kg every 2 weeks (Q2W)
Study: 32409691
Drug: isatuximab 10
Normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: isatuximab 10 mg/kg Q2W/Q4W
Study: 32409691
Drug: isatuximab 10
Normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: isatuximab 10 mg/kg Q2W
Study: 32409691
Drug: isatuximab 20
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: isatuximab 20 mg/kg QW(1 cycle)/Q2W
Study: 32409691
Drug: isatuximab (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: isatuximab (doses ≥10 mg/kg)
Study: 32961119
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks for four doses, then every 12 weeks until 1 year or until disease recurrence, unacceptable toxicity, or withdrawal)
Study: 32961119
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg every 3 weeks for four doses, then every 12 weeks until 1 year or until disease recurrence, unacceptable toxicity, or withdrawal)
Study: 36174848
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral once per month for up to 5 years)
Study: 33977364
Drug: ModelCI (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ModelCI (combination of clinical factors and imaging characteristics)
Study: 35244287
Drug: Recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle-stimulating hormone (rFSH) at doses of 0.5, 1.1, and 2.2 IU/kg/d
Study: 35244287
Drug: Recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle-stimulating hormone (rFSH) at all doses
Study: 32267573
Drug: Vicagrel (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel (24 mg loading dose, 6 mg maintenance dose)
Study: 32267573
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, 75 mg maintenance dose)
Study: 33538934
Drug: Video intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video intervention adjuncts (VIAs) paired with dialectical behavior therapy (DBT) for IPV skills group
Study: 36975019
Drug: Antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agents
Study: 32105820
Drug: Prostaglandin F2α
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2α (PGF2α) injection into the cervix before and after surgery
Study: 32105820
Drug: Prostaglandin F2α
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2α (PGF2α) injection
Study: 32105820
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PGF2α injection)
Study: 35157055
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (IPE), 4 g/d
Study: 35802375
Drug: 195-mg transdermal
Normalized name: levodopa 195 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 195-mg transdermal cannabidiol
Study: 35802375
Drug: 390-mg transdermal
Normalized name: guaifenesin 390 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 390-mg transdermal cannabidiol
Study: 35802375
Drug: Cannabidiol (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol (combined 195-mg and 390-mg)
Study: 34587373
Drug: Individualized BP-lowering
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized BP-lowering treatment
Study: 34587373
Drug: Standard BP-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BP-lowering treatment
Study: 33601858
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily for 5 days along with general supportive treatment
Study: 32524129
Drug: Dynamic enteral
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic enteral and parenteral nutrition support with ω‐3 fish oil fat milk injection and glutamine
Study: 32524129
Drug: Routine postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine postoperative enteral and parenteral camp support
Study: 32524129
Drug: Dynamic enteral
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic enteral and parenteral nutrition support
Study: 35584865
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.2 mg/kg), doxorubicin (25 mg/m2), vinblastine (6 mg/m2), dacarbazine (375 mg/m2), and rituximab (375 mg/m2) for four or six cycles.
Study: 35584865
Drug: Brentuximab vedotin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brentuximab vedotin, rituximab, and risk-adapted chemotherapy.
Study: 39315334
Drug: Bivalent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent HPV vaccine
Study: 35926984
Drug: Intra-arterial thrombolytics
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial thrombolytics (urokinase median dose 250,000 IU, alteplase median dose 20 mg)
Study: 32191400
Drug: UDCA 300
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 300 mg twice daily
Study: 32191400
Drug: UDCA 300
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 300 mg twice daily for 4 weeks followed by UDCA 300 mg twice daily and metformin 500 mg twice daily for 4 weeks
Study: 36205206
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (hydroxychloroquine)
Study: 32546269
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy for 2 weeks
Study: 32546269
Drug: Conventional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotic therapy (4-6 weeks)
Study: 35871815
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular glucocorticoid injection (120 mg) and a 1‐year course of oral methotrexate (up to 25 mg/week)
Study: 35871815
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single injection and tablets for 1 year)
Study: 35604466
Drug: Language therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Language therapy (control group)
Study: 35984159
Drug: Empirical concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical concomitant therapy (CoT): rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 14 days
Study: 35984159
Drug: Tailored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapy (TaT): rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 14 days for point mutation-negative patients; rabeprazole 20 mg twice daily, metronidazole 500 mg thrice daily, bismuth 120 mg, and tetracycline 500 mg 4 times daily for 14 days for point mutation-positive patients
Study: 35984159
Drug: Empirical concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical concomitant therapy (CoT) in point mutation-positive patients
Study: 35984159
Drug: Tailored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapy (TaT) in point mutation-positive patients
Study: 35466156
Drug: High-dose pitavastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pitavastatin (4 mg/day × 4 days)
Study: 35510343
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion intervention (individual support to improve oral health)
Study: 34541982
Drug: PRIME needle-free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRIME needle-free injection system
Study: 35809825
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 90% efficacy
Study: 33684506
Drug: sucrose (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucrose (80 g/day)
Study: 33684506
Drug: fructose (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: fructose (80 g/day)
Study: 33684506
Drug: glucose (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: glucose (80 g/day)
Study: 32080148
Drug: traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional treatment + intravenous infusion of edaravone 30 mg twice a day for 14 days
Study: 35255966
Drug: MenSC-derived secretome
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenSC-derived secretome treatment (5 mL intravenous infusions for five days)
Study: 35255966
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo, 5 mL intravenous infusions for five days)
Study: 35255966
Drug: MenSC-derived secretome
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenSC-derived secretome treatment
Study: 34837169
Drug: Palbociclib test
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib test formulation (125 mg) under fasting condition
Study: 34837169
Drug: Palbociclib test
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib test formulation (125 mg) under fed condition
Study: 34837169
Drug: Palbociclib reference
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib reference formulation (125 mg) under fasting condition
Study: 34837169
Drug: Palbociclib reference
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib reference formulation (125 mg) under fed condition
Study: 32808029
Drug: L-cysteine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-cysteine (1200 mg)
Study: 32808029
Drug: L-cysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-cysteine (600 mg)
Study: 35895764
Drug: BLS (bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLS (bupivacaine liposomal suspension)
Study: 32789530
Drug: Bag-of-features (BOF)
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bag-of-features (BOF) features with augmentation from contrast-enhanced MRI (CE-MRI)
Study: 32493383
Drug: Modified Diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Diagnostic Strategy (MODS) with D-dimer threshold raised to 1000 ng/ml if no items of the YEARS score are present.
Study: 32493383
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with D-dimer threshold of 500 ng/ml for patients aged 50 years or younger and age × 10 for older patients.
Study: 35293783
Drug: Erythromycin 400
Normalized name: ERYTHROMYCIN 400 mg in 5.2 g TOPICAL POWDER [API E.M ERYTHROMYCIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 400 mg twice daily for 4 weeks
Study: 35293783
Drug: Azithromycin 125
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 125 mg twice daily for 4 weeks
Study: 32910863
Drug: Cytoflavin antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin antioxidant energy therapy
Study: 33789267
Drug: Intratympanic triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic triamcinolone acetonide injections (up to 3 injections at 1-week intervals)
Study: 33789267
Drug: Intratympanic triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic triamcinolone acetonide injections
Study: 34192419
Drug: BAY 2433334
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 2433334 (5–150 mg as oral solution or immediate-release tablets)
Study: 34192419
Drug: BAY 2433334
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 2433334 (5 mg tablets) with a high-calorie breakfast
Study: 32971450
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (500 μg/day)
Study: 35748058
Drug: YH4808 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 at 30, 50, 100, 200, 400, 600, and 800 mg (single oral dose)
Study: 35748058
Drug: YH4808 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 at 100, 200, and 400 mg (multiple once-daily oral doses for 7 days)
Study: 35748058
Drug: Omeprazole at
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole at 40 mg (active comparator)
Study: 35748058
Drug: YH4808 (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (repeated doses)
Study: 32371537
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with trastuzumab-containing regimens
Study: 33728848
Drug: ipidacrine added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipidacrine added to traditional therapy (n=50)
Study: 33728848
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n=42)
Study: 34818363
Drug: Yokukansan (YKS),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yokukansan (YKS), 2.5 g doses before sleeping on the night before surgery and 2 hours before anesthesia induction
Study: 34818363
Drug: Control (CNT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CNT), no medication preoperatively
Study: 35500960
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy along with Low Intensity Pulsed Ultrasound (LIPUS)
Study: 35500960
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy (Control Group)
Study: 35565110
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (DTG, waiting list control)
Study: 35491682
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (IVK) administered pre-operatively
Study: 35491682
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (IVK) administered intra-operatively
Study: 35491682
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (IVK) administered post-operatively
Study: 35709509
Drug: CBL-514 injection
Normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBL-514 injection at a dose of 2.0 mg/cm2 (300 mg)
Study: 35709509
Drug: CBL-514 injection
Normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBL-514 injection at a dose of 1.6 mg/cm2 (240 mg)
Study: 35709509
Drug: CBL-514 injection
Normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBL-514 injection at a dose of 1.2 mg/cm2 (180 mg)
Study: 33470152
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulation restarted after 1 week
Study: 33470152
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulation restarted after 2 weeks
Study: 33470152
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulation restarted after 4 weeks
Study: 34651171
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) hydration